Equity
€875,529 ▲ 2.5%
DEMAPHAR has made a profit without a break since 2020.
DEMAPHAR
Part of the group
42 companies
Lifetime
19 annual accounts with figures on one time axis, 38 filings since 1988peak €338,177 (2007)
€170,645▲ 11.1%
lowest -€32,452 (2009)
€21,018▲ 13.0%
peak €875,529 (2025)
€875,529▲ 2.5%
€90,049▼ 3.0%
peak 6.1 FTE (2009)
2 FTEunchanged
Board7 names since 2020
3 directors and 2 others
Owners2 names in the annual accounts
100%
Documentsfilings and deeds
12-05-202680 days before the deadline
2025financial year
A quiet year: no large shift against the year before.
Key points
from the 2025 annual accountsTurnover
≈ €800,000 estimated
The accounts state no turnover.
Staff
2 FTE from 6.1 in 2009
Between 2009 and 2025, 67% of the full-time equivalents disappeared.
Filings
38 annual accounts since 1988
The last five annual accounts were filed 45 to 80 days before the end of the period.
Board
1 joined · 1 left
Board changed. Latest change 19-05-2026 · 3 in office.
Position in the sector
90.7%
Higher solvency than 95% of companies in retail trade. Sector median 33.4% · 2,453 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 17,044 companies had the same profile as DEMAPHAR has now. Each dot stands for 43 companies, two years later.
94.3%
were still trading
5.0%
stopped another way
0.5%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,044 companies, not a prediction for DEMAPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Managing director,
Managing director
Director,
- 100%score equity €33.0m (2025) · 2025 annual accounts of
Recent changes
1 director appointed, 1 resignation, 1 reappointment
Resignation: · Appointment: · Permanent representative: · General meeting of 19-05-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0433580102
1 director appointed, 1 resignation
Appointment: · Permanent representatives: and · Resignation: · Board meeting of 01-09-2022 · Gazette deed
1 director appointed, 2 resignations
Change of role: , from director to managing director · Resignations: and · Appointment: (chair) · General meeting of 22-12-2020 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| DEMAPHAR Mons | €1.0m | €170,645 | 90.7% | 2 |
| Apotheek N. Debaere Wevelgem | €1.1m | €170,915 | 54.6% | 2 |
| PHARMACIE LENOIR La Louvière | €0.8m | €161,800 | 59.9% | 1.9 |
| PHARMACIE CASTRIQUE Comines-Warneton | €0.9m | €196,653 | 45.2% | 2.5 |
| PHARMACIE DE MARIE - LE ROEULX CENTRE Le Roeulx | €0.8m | €162,644 | 51.4% | 2.6 |
| IMMO DEBAR Lasne | €0.9m | €196,728 | 29.4% | 2 |
| APOTHEEK VELGHE Maarkedal | €1.1m | €189,820 | 12.5% | 1.7 |
These companies have the same main activity as DEMAPHAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €826,000 and €1.1m, founded between 1987 and 1992.
Official details
Source: KBO- Status
- Active since 09-03-1988Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.036.224.9887033 Mons, since 01-12-1988
- Financial year end
- 31 December
- Peppol
- Reachable since 06-06-2025
Annual accounts 2025
- €965,578▲ 1.9%
- Employeeson 31-12-2025
- 2=
- Filing
- Filed on 12-05-2026, 80 days before the end of the filing period
Companies linked to DEMAPHAR
Parent and group
Insights on DEMAPHAR
DEMAPHAR has existed since 1988. The gross margin fell from €338,177 in 2007 to €170,645 in 2025 and staff from 5.6 to 2 full-time equivalents.
holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DEMAPHAR
- What is the company number of DEMAPHAR?
- The company number of DEMAPHAR is 0433.580.102. The VAT number is the same number with BE in front: BE 0433.580.102.
- Where is DEMAPHAR based?
- The registered office is at Rue de l'Etang Derbaix (C.) 137, 7033 Mons.Company details
- What does DEMAPHAR do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of DEMAPHAR?
- DEMAPHAR is a private limited company (BV).
- When was DEMAPHAR founded?
- DEMAPHAR was founded on 09-03-1988.
- Is DEMAPHAR still active?
- Yes, DEMAPHAR is an active enterprise in the KBO register.
- How many employees does DEMAPHAR have?
- DEMAPHAR had an average of 2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does DEMAPHAR fall under?
- In its 2025 annual accounts, DEMAPHAR states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of DEMAPHAR?
- The turnover in financial year 2025 is ≈ €800,000. This figure is estimated from the gross margin of €170,645 and 52 comparable companies (NACE 477). It probably lies between €540,000 and €1.5m.
- Is DEMAPHAR profitable?
- In financial year 2025, DEMAPHAR made a profit of €21,018.
- Where can I find the annual accounts of DEMAPHAR?
- DEMAPHAR filed 38 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DEMAPHAR due?
- DEMAPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.